Phase I/II trial to establish the safety and preliminary efficacy of the combination of docetaxel, prednisone, and SOM 230 in metastatic castrate-resistant prostate cancer (CRPC).
H. M. Vankayala
No relevant relationships to disclose
L. K. Heilbrun
No relevant relationships to disclose
J. A. Fontana
No relevant relationships to disclose
U. N. Vaishampayan
Honoraria - Novartis
Research Funding - Novartis